S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Russia Ignites West's Battle for Energy Independence (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Which Semiconductor Stocks Are Ready For Big Price Moves?
Wind energy boom and golden eagles collide in the US West
Big Potential Stock For 2022 (Ad)
Lowe’s Stands Out Amid Q2 Retail Reports 
US to hold trade talks with Taiwan, island drills military
Egypt's central bank governor resigns as economic woes mount
Big Potential Stock For 2022 (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Russia Ignites West's Battle for Energy Independence (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Which Semiconductor Stocks Are Ready For Big Price Moves?
Wind energy boom and golden eagles collide in the US West
Big Potential Stock For 2022 (Ad)
Lowe’s Stands Out Amid Q2 Retail Reports 
US to hold trade talks with Taiwan, island drills military
Egypt's central bank governor resigns as economic woes mount
Big Potential Stock For 2022 (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Russia Ignites West's Battle for Energy Independence (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Which Semiconductor Stocks Are Ready For Big Price Moves?
Wind energy boom and golden eagles collide in the US West
Big Potential Stock For 2022 (Ad)
Lowe’s Stands Out Amid Q2 Retail Reports 
US to hold trade talks with Taiwan, island drills military
Egypt's central bank governor resigns as economic woes mount
Big Potential Stock For 2022 (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Russia Ignites West's Battle for Energy Independence (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Which Semiconductor Stocks Are Ready For Big Price Moves?
Wind energy boom and golden eagles collide in the US West
Big Potential Stock For 2022 (Ad)
Lowe’s Stands Out Amid Q2 Retail Reports 
US to hold trade talks with Taiwan, island drills military
Egypt's central bank governor resigns as economic woes mount
Big Potential Stock For 2022 (Ad)
NYSE:DGX

Quest Diagnostics - DGX Stock Forecast, Price & News

$137.84
-2.69 (-1.91%)
(As of 08/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$137.53
$140.30
50-Day Range
$127.07
$141.10
52-Week Range
$125.33
$174.16
Volume
715,276 shs
Average Volume
806,976 shs
Market Capitalization
$16.07 billion
P/E Ratio
11.47
Dividend Yield
1.88%
Price Target
$150.36

Quest Diagnostics MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
9.1% Upside
$150.36 Price Target
Short Interest
Bearish
4.14% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-0.66
Upright™ Environmental Score
News Sentiment
0.49mentions of Quest Diagnostics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$40.11 M Sold Last Quarter
Proj. Earnings Growth
-14.04%
From $9.69 to $8.33 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

633rd out of 1,122 stocks

Medical Laboratories Industry

17th out of 28 stocks

DGX stock logo

About Quest Diagnostics (NYSE:DGX) Stock

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Quest Diagnostics Stock Performance

DGX traded down $2.69 during mid-day trading on Wednesday, reaching $137.84. 715,276 shares of the company traded hands, compared to its average volume of 1,089,171. The stock has a market capitalization of $16.07 billion, a P/E ratio of 11.47 and a beta of 1.00. The company has a quick ratio of 1.42, a current ratio of 1.54 and a debt-to-equity ratio of 0.62. The company's fifty day moving average price is $135.32 and its 200-day moving average price is $136.36. Quest Diagnostics has a 52-week low of $125.33 and a 52-week high of $174.16.

Quest Diagnostics (NYSE:DGX - Get Rating) last announced its earnings results on Thursday, July 21st. The medical research company reported $2.36 earnings per share for the quarter, beating analysts' consensus estimates of $2.26 by $0.10. The business had revenue of $2.45 billion during the quarter, compared to analyst estimates of $2.34 billion. Quest Diagnostics had a net margin of 14.02% and a return on equity of 24.62%. The company's quarterly revenue was down 3.8% compared to the same quarter last year. During the same period in the previous year, the business earned $3.18 EPS. On average, sell-side analysts expect that Quest Diagnostics will post 9.69 EPS for the current year.

Quest Diagnostics Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 19th. Shareholders of record on Tuesday, October 4th will be paid a dividend of $0.66 per share. The ex-dividend date of this dividend is Monday, October 3rd. This represents a $2.64 dividend on an annualized basis and a yield of 1.92%. Quest Diagnostics's dividend payout ratio is presently 21.96%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Wells Fargo & Company upped their target price on shares of Quest Diagnostics from $145.00 to $150.00 and gave the stock an "equal weight" rating in a research report on Monday, April 25th. StockNews.com raised shares of Quest Diagnostics from a "hold" rating to a "buy" rating in a research report on Thursday, July 7th. UBS Group upped their target price on shares of Quest Diagnostics from $139.00 to $150.00 in a research report on Sunday, April 24th. Finally, Bank of America cut their price objective on shares of Quest Diagnostics from $166.00 to $163.00 and set a "buy" rating on the stock in a research report on Friday, April 22nd. Six research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Quest Diagnostics currently has a consensus rating of "Hold" and a consensus target price of $150.36.

Insider Buying and Selling at Quest Diagnostics

In other news, CEO Stephen H. Rusckowski sold 282,408 shares of the business's stock in a transaction on Tuesday, May 24th. The shares were sold at an average price of $140.12, for a total transaction of $39,571,008.96. Following the completion of the sale, the chief executive officer now owns 334,833 shares of the company's stock, valued at approximately $46,916,799.96. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, Director Timothy M. Ring sold 2,000 shares of the business's stock in a transaction on Monday, August 1st. The shares were sold at an average price of $136.04, for a total transaction of $272,080.00. Following the completion of the sale, the director now owns 23,933 shares of the company's stock, valued at approximately $3,255,845.32. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Stephen H. Rusckowski sold 282,408 shares of the company's stock in a transaction on Tuesday, May 24th. The stock was sold at an average price of $140.12, for a total transaction of $39,571,008.96. Following the completion of the transaction, the chief executive officer now directly owns 334,833 shares of the company's stock, valued at approximately $46,916,799.96. The disclosure for this sale can be found here. In the last ninety days, insiders sold 286,408 shares of company stock worth $40,110,029. Insiders own 1.70% of the company's stock.

Receive DGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

DGX Stock News Headlines

Quest Diagnostics Adds HCV Screening To Its New Obstetrics Test Panel
Quest Diagnostics Sponsors Modern Healthcare Webinar
2 Monkeypox Stocks to Watch This Week
Quest Diagnostics, Inc.
See More Headlines
Receive DGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

DGX Company Calendar

Ex-Dividend for 7/20 Dividend
7/05/2022
Dividend Payable
7/20/2022
Last Earnings
7/21/2022
Today
8/18/2022
Next Earnings (Estimated)
10/20/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
Health Care Services
Sector
Medical
CUSIP
74834L10
Employees
49,000
Year Founded
1967

Price Target and Rating

Average Stock Price Forecast
$150.36
High Stock Price Forecast
$170.00
Low Stock Price Forecast
$129.00
Forecasted Upside/Downside
+9.1%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
9 Analysts

Profitability

Net Income
$2.00 billion
Pretax Margin
18.25%

Debt

Sales & Book Value

Annual Sales
$10.79 billion
Cash Flow
$17.88 per share
Book Value
$55.31 per share

Miscellaneous

Free Float
114,624,000
Market Cap
$16.07 billion
Optionable
Optionable
Beta
1.00

Social Links















DGX Stock - Frequently Asked Questions

Should I buy or sell Quest Diagnostics stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last twelve months. There are currently 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" DGX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DGX, but not buy additional shares or sell existing shares.
View DGX analyst ratings
or view top-rated stocks.

What is Quest Diagnostics' stock price forecast for 2022?

9 Wall Street research analysts have issued twelve-month target prices for Quest Diagnostics' shares. Their DGX share price forecasts range from $129.00 to $170.00. On average, they expect the company's share price to reach $150.36 in the next twelve months. This suggests a possible upside of 9.1% from the stock's current price.
View analysts price targets for DGX
or view top-rated stocks among Wall Street analysts.

How have DGX shares performed in 2022?

Quest Diagnostics' stock was trading at $173.01 at the beginning of the year. Since then, DGX shares have decreased by 20.3% and is now trading at $137.84.
View the best growth stocks for 2022 here
.

When is Quest Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 20th 2022.
View our DGX earnings forecast
.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Incorporated (NYSE:DGX) released its quarterly earnings data on Thursday, July, 21st. The medical research company reported $2.36 earnings per share for the quarter, beating analysts' consensus estimates of $2.26 by $0.10. The medical research company had revenue of $2.45 billion for the quarter, compared to the consensus estimate of $2.34 billion. Quest Diagnostics had a net margin of 14.02% and a trailing twelve-month return on equity of 24.62%. The firm's quarterly revenue was down 3.8% on a year-over-year basis. During the same period in the prior year, the firm posted $3.18 EPS.
Read the conference call transcript
.

How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics?

Quest Diagnostics announced a quarterly dividend on Wednesday, August 10th. Shareholders of record on Tuesday, October 4th will be paid a dividend of $0.66 per share on Wednesday, October 19th. This represents a $2.64 annualized dividend and a yield of 1.92%. The ex-dividend date is Monday, October 3rd.
Read our dividend analysis for DGX
.

Is Quest Diagnostics a good dividend stock?

Quest Diagnostics (NYSE:DGX) pays an annual dividend of $2.64 per share and currently has a dividend yield of 1.88%. The company has been increasing its dividend for 13 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 21.96%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, DGX will have a dividend payout ratio of 31.69% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for DGX.

How will Quest Diagnostics' stock buyback program work?

Quest Diagnostics declared that its board has authorized a stock buyback plan on Thursday, February 4th 2021, which permits the company to repurchase $1,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to purchase up to 6.1% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's management believes its stock is undervalued.

What guidance has Quest Diagnostics issued on next quarter's earnings?

Quest Diagnostics issued an update on its FY 2022 earnings guidance on Friday, July, 29th. The company provided earnings per share guidance of $9.55-$9.95 for the period, compared to the consensus estimate of $9.33. The company issued revenue guidance of $9.50 billion-$9.75 billion, compared to the consensus revenue estimate of $9.42 billion.

What is Steve Rusckowski's approval rating as Quest Diagnostics' CEO?

1,053 employees have rated Quest Diagnostics Chief Executive Officer Steve Rusckowski on Glassdoor.com. Steve Rusckowski has an approval rating of 78% among the company's employees.

What other stocks do shareholders of Quest Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quest Diagnostics investors own include CA (CA), BlackRock (BLK), Johnson & Johnson (JNJ), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), Abbott Laboratories (ABT), NVIDIA (NVDA), Intel (INTC) and Cisco Systems (CSCO).

What is Quest Diagnostics' stock symbol?

Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX."

Who are Quest Diagnostics' major shareholders?

Quest Diagnostics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include State Street Corp (5.19%), Victory Capital Management Inc. (2.58%), Grantham Mayo Van Otterloo & Co. LLC (1.49%), Northern Trust Corp (1.26%), Pictet Asset Management SA (1.06%) and UBS Asset Management Americas Inc. (0.99%). Insiders that own company stock include Catherine T Doherty, Daniel Stanzione, Gail R Wilensky, J E Davis, Manner Carrie Eglinton, Mark Guinan, Michael E Prevoznik, Michael J Deppe, Stephen H Rusckowski, Stephen H Rusckowski and Timothy M Ring.
View institutional ownership trends
.

How do I buy shares of Quest Diagnostics?

Shares of DGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Quest Diagnostics' stock price today?

One share of DGX stock can currently be purchased for approximately $137.84.

How much money does Quest Diagnostics make?

Quest Diagnostics (NYSE:DGX) has a market capitalization of $16.07 billion and generates $10.79 billion in revenue each year. The medical research company earns $2.00 billion in net income (profit) each year or $12.02 on an earnings per share basis.

How many employees does Quest Diagnostics have?

The company employs 49,000 workers across the globe.

Does Quest Diagnostics have any subsidiaries?
The following companies are subsidiares of Quest Diagnostics: AmeriPath, AmeriPath Cincinnati Inc. (OH), AmeriPath Cleveland Inc. (OH), AmeriPath Consolidated Labs Inc. (FL), AmeriPath Florida LLC (DE), AmeriPath Hospital Services Florida LLC (DE), AmeriPath Inc. (DE), AmeriPath Indianapolis PC (IN), AmeriPath Kentucky Inc. (KY), AmeriPath Lubbock 5.01(A) Corporation (TX), AmeriPath New York LLC (DE), AmeriPath Texas Inc. (DE), AmeriPath Tucson Inc. (AZ), American Medical Laboratories, American Medical Laboratories Incorporated (DE), Associated Clinical Laboratories L.P. (PA), Associated Clinical Laboratories of Pennsylvania L.L.C. (PA), Athena Diagnostics, Athena Diagnostics Inc. (DE), Blueprint Genetics, Blueprint Genetics FZ-LLC (UAE), Blueprint Genetics Inc. (DE), Blueprint Genetics Oy (Finland), California Laboratory Associates, Cape Cod Healthcare - Business, Celera, ClearPoint Diagnostic, Clearpoint Diagnostic Laboratories LLC (TX), Cleveland HeartLab, Cleveland HeartLab Inc. (DE), Clinical Laboratory Partners, Colorado Pathology Consultants P.C. (CO), ConVerge Diagnostic Services, Consolidated DermPath Inc. (DE), DFW 5.01(a) Corporation (TX), DGXWMT JV LLC (DE), Dermatopathology of Wisconsin S.C. (WI), Diagnostic Laboratory of Oklahoma LLC (OK), Diagnostic Pathology Services Inc. (OK), Diagnostic Reference Services Inc. (MD), ExamOne Canada Inc. (New Brunswick), ExamOne LLC (DE), ExamOne World Wide Inc. (PA), ExamOne World Wide of NJ Inc. (NJ), Focus Diagnostics, HemoCue, Hoffman M.D. Associated Pathologists Chartered (NV), Institute for Dermatopathology Inc. (PA), Isabella Street Urban Renewal LLC (NJ), Kailash B. Sharma M.D. Inc. (GA), Kilpatrick Pathology P.A. (NC), LabOne, LabOne LLC (MO), LabOne of Ohio Inc. (DE), Laboratorio de Analisis Biomedicos S.A. (Mexico), Lancet Labs, MACL, Med Fusion LLC (TX), Med fusion, MedPlus, Mid America Clinical Laboratories LLC (IN), Nomad Massachusetts Inc. (MA), Nuclear Medicine and Pathology Associates (GA), Ocmulgee Medical Pathology Association Inc. (GA), Pathology Building Partnership (MD) (gen. ptnrshp.), PeaceHealth Laboratories, PhenoPath Laboratories, PhenoPath Laboratories PLLC (WA), Q Squared Solutions Holdings LLC (DE), Q Squared Solutions Holdings Limited (UK), Quest Diagnostics (Shanghai) Co. Ltd. (China), Quest Diagnostics Brasil Holdings Ltd. (UK), Quest Diagnostics Clinical Laboratories, Quest Diagnostics Clinical Laboratories Inc. (DE), Quest Diagnostics Domestic Holder LLC (DE), Quest Diagnostics HTAS India Private Limited (India), Quest Diagnostics Health & Wellness LLC (DE), Quest Diagnostics Holdings Incorporated (DE), Quest Diagnostics Holdings Ltd. (UK), Quest Diagnostics Incorporated (MD), Quest Diagnostics Incorporated (NV), Quest Diagnostics India Private Limited (India), Quest Diagnostics Infectious Disease Inc. (DE), Quest Diagnostics International Holdings Limited (UK), Quest Diagnostics International LLC (DE), Quest Diagnostics Investments LLC (DE), Quest Diagnostics Ireland Limited (Ireland), Quest Diagnostics LLC (CT), Quest Diagnostics LLC (IL), Quest Diagnostics LLC (MA), Quest Diagnostics Massachusetts LLC (MA), Quest Diagnostics Mexico Holding Company Trust (Mexico), Quest Diagnostics Mexico S de RL de CV (Mexico), Quest Diagnostics Nichols Institute (CA), Quest Diagnostics Nichols Institute Inc. (VA), Quest Diagnostics Receivables Inc. (DE), Quest Diagnostics Subsidiary Holdings Ltd. (UK), Quest Diagnostics TB LLC (DE), Quest Diagnostics Terracotta LLC (DE), Quest Diagnostics Venture LLC (PA), Quest Diagnostics Ventures LLC (DE), Quest Diagnostics do Brasil Ltda. (Brazil), Quest Diagnostics of Pennsylvania Inc. (DE), Quest Diagnostics of Puerto Rico Inc. (PR), Quest HealthConnect LLC (CA), ReproSource, Reprosource Fertility Diagnostics Inc. (MA), Solstas Lab Partners, Sonora Quest Laboratories LLC (AZ), Specialty Laboratories Inc. (CA), Summit Health, UMass Memorial Medical Center - Anatomic Pathology Outreach Laboratory Business, Unilab Corporation, and Unilab Corporation (DE).
Read More
When was Quest Diagnostics founded?

Quest Diagnostics was founded in 1967.

How can I contact Quest Diagnostics?

Quest Diagnostics' mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07094. The official website for the company is www.questdiagnostics.com. The medical research company can be reached via phone at (973) 520-2700, via email at investor@questdiagnostics.com, or via fax at 201-462-4169.

This page (NYSE:DGX) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.